Hindustan Bio Sciences Valuation

Is 532041 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 532041 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 532041's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 532041's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 532041?

Key metric: As 532041 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 532041. This is calculated by dividing 532041's market cap by their current earnings.
What is 532041's PE Ratio?
PE Ratio	39.3x
Earnings	₹2.62m
Market Cap	₹102.92m

532041 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	8.7x
Enterprise Value/EBITDA	47.9x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 532041's PE Ratio compare to its peers?

The above table shows the PE ratio for 532041 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	39.5x
NIRMAN Nirman Agri Genetics	13.4x	n/a	₹2.4b
532039 Zenotech Laboratories	69.9x	n/a	₹4.7b
524606 Beryl Drugs	48.4x	n/a	₹163.8m
531210 Colinz Laboratories	26.3x	n/a	₹132.3m
532041 Hindustan Bio Sciences	39.3x	n/a	₹102.9m

Price-To-Earnings vs Peers: 532041 is good value based on its Price-To-Earnings Ratio (39.3x) compared to the peer average (39.5x).

Price to Earnings Ratio vs Industry

How does 532041's PE Ratio compare vs other companies in the Asian Biotechs Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 532041 is expensive based on its Price-To-Earnings Ratio (39.3x) compared to the Asian Biotechs industry average (33x).

Price to Earnings Ratio vs Fair Ratio

What is 532041's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

532041 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	39.3x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 532041's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Bal Pharma

₹2.2b

Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.

BALPHARMA

₹134.50

11.6%

27.4%

Mercury Laboratories

₹1.1b

Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.

538964

₹911.45

-3.5%

18.7%

Caplin Point Laboratories

₹147.7b

Engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India.

CAPLIPOINT

₹1,942.80

-0.4%

58.1%